Saturday 31 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

62.55 1.16 +1.89%

Follow BMY

Alert me

Market cap: $125.4B
P/E: 13.8×
Fwd P/E: 11.9×
Dividend yield: 4.03%
F-score: 8/9
Altman Z: 2.14
Beneish M: −2.69
Dividend safety: 63/100

Overview Business Profile Earnings & Analysis Segments Filings

Bristol Myers Squibb Company (BMY) revenue by segment, product and region

	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019	Q4 FY2018	Q3 FY2018	Q2 FY2018	Q1 FY2018	Q4 FY2017	Q3 FY2017	Q2 FY2017	Q1 FY2017
Eliquis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Opdivo	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Orencia	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Mature Products And All Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sprycel	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Yervoy	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revlimid	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Empliciti	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Pomalyst/Imnovid	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Abraxane	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Inrebic	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reblozyl	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Zeposia	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Onureg	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Breyanzi	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Abecma	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Baraclude	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Vidaza	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Hepatitis C Portfolio	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sustiva Franchise	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reyataz	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Abilify	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Erbitux	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Plavix	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Avapro Avalide	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Onglyza Kombiglyze	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nulojix	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Bristol Myers Squibb Company (BMY) revenue by segment, product and region

Stockrow Weekly